Stay updated on Biomarker Analysis in High PD-L1 NSCLC Clinical Trial
Sign up to get notified when there's something new on the Biomarker Analysis in High PD-L1 NSCLC Clinical Trial page.

Latest updates to the Biomarker Analysis in High PD-L1 NSCLC Clinical Trial page
- Check3 days agoChange DetectedA new revision entry (v3.4.3) was added to the record history, and the prior revision (v3.4.2) was removed.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedA new revision entry (Revision: v3.4.2) was added to the history, and a government funding lapse notice along with the prior revision entry (Revision: v3.4.1) was removed. These changes are administrative and do not modify core study data or page behavior. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

- Check39 days agoChange DetectedNotice about government funding appears at the top, and the record history now shows a new revision (v3.4.1) replacing the previous v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

- Check46 days agoChange DetectedAdds UI elements and legends to the history view (Show glossary; green for additions and red for deletions) and updates the revision label from v3.3.4 to v3.4.0.SummaryDifference1%

- Check60 days agoChange DetectedAdded revision entry v3.3.4 to the Record History. Removed v3.3.3 from the version list.SummaryDifference0.1%

- Check81 days agoChange DetectedA new revision entry 'Revision: v3.3.3' was added to the Record History, and 'HHS Vulnerability Disclosure' along with the previous 'Revision: v3.3.2' were removed from the footer; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Biomarker Analysis in High PD-L1 NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Biomarker Analysis in High PD-L1 NSCLC Clinical Trial page.